List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Neurological Disorder Drugs Revenue
1.4 Market Analysis by Type
1.4.1 Global Neurological Disorder Drugs Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Antipsychotic
1.4.3 Hypnotic & Sedative
1.4.4 Analgesics
1.4.5 Anticoagulants
1.5 Market by Application
1.5.1 Global Neurological Disorder Drugs Market Share by Application: 2022-2027
1.5.2 Hospital
1.5.3 Clinic
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Neurological Disorder Drugs Market
1.8.1 Global Neurological Disorder Drugs Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Neurological Disorder Drugs Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Neurological Disorder Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Neurological Disorder Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Neurological Disorder Drugs Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Neurological Disorder Drugs Sales Volume Market Share by Region (2016-2021)
3.2 Global Neurological Disorder Drugs Sales Revenue Market Share by Region (2016-2021)
3.3 North America Neurological Disorder Drugs Sales Volume
3.3.1 North America Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.3.2 North America Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Neurological Disorder Drugs Sales Volume
3.4.1 East Asia Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Neurological Disorder Drugs Sales Volume (2016-2021)
3.5.1 Europe Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Neurological Disorder Drugs Sales Volume (2016-2021)
3.6.1 South Asia Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Neurological Disorder Drugs Sales Volume (2016-2021)
3.7.1 Southeast Asia Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Neurological Disorder Drugs Sales Volume (2016-2021)
3.8.1 Middle East Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Neurological Disorder Drugs Sales Volume (2016-2021)
3.9.1 Africa Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Neurological Disorder Drugs Sales Volume (2016-2021)
3.10.1 Oceania Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Neurological Disorder Drugs Sales Volume (2016-2021)
3.11.1 South America Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.11.2 South America Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Neurological Disorder Drugs Sales Volume (2016-2021)
3.12.1 Rest of the World Neurological Disorder Drugs Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Neurological Disorder Drugs Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Neurological Disorder Drugs Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Neurological Disorder Drugs Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Neurological Disorder Drugs Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Neurological Disorder Drugs Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Neurological Disorder Drugs Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Neurological Disorder Drugs Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Neurological Disorder Drugs Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Neurological Disorder Drugs Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Neurological Disorder Drugs Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Neurological Disorder Drugs Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Neurological Disorder Drugs Sales Volume Market Share by Type (2016-2021)
14.2 Global Neurological Disorder Drugs Sales Revenue Market Share by Type (2016-2021)
14.3 Global Neurological Disorder Drugs Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Neurological Disorder Drugs Consumption Volume by Application (2016-2021)
15.2 Global Neurological Disorder Drugs Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Neurological Disorder Drugs Business
16.1 Novartis AG
16.1.1 Novartis AG Company Profile
16.1.2 Novartis AG Neurological Disorder Drugs Product Specification
16.1.3 Novartis AG Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 GlaxoSmithKline plc
16.2.1 GlaxoSmithKline plc Company Profile
16.2.2 GlaxoSmithKline plc Neurological Disorder Drugs Product Specification
16.2.3 GlaxoSmithKline plc Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Merck & Co.
16.3.1 Merck & Co. Company Profile
16.3.2 Merck & Co. Neurological Disorder Drugs Product Specification
16.3.3 Merck & Co. Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Bayer AG
16.4.1 Bayer AG Company Profile
16.4.2 Bayer AG Neurological Disorder Drugs Product Specification
16.4.3 Bayer AG Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 AstraZeneca
16.5.1 AstraZeneca Company Profile
16.5.2 AstraZeneca Neurological Disorder Drugs Product Specification
16.5.3 AstraZeneca Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Boehringer Ingelheim GmbH
16.6.1 Boehringer Ingelheim GmbH Company Profile
16.6.2 Boehringer Ingelheim GmbH Neurological Disorder Drugs Product Specification
16.6.3 Boehringer Ingelheim GmbH Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Teva Pharmaceutical
16.7.1 Teva Pharmaceutical Company Profile
16.7.2 Teva Pharmaceutical Neurological Disorder Drugs Product Specification
16.7.3 Teva Pharmaceutical Neurological Disorder Drugs Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Neurological Disorder Drugs Manufacturing Cost Analysis
17.1 Neurological Disorder Drugs Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Neurological Disorder Drugs
17.4 Neurological Disorder Drugs Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Neurological Disorder Drugs Distributors List
18.3 Neurological Disorder Drugs Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Neurological Disorder Drugs (2022-2027)
20.2 Global Forecasted Revenue of Neurological Disorder Drugs (2022-2027)
20.3 Global Forecasted Price of Neurological Disorder Drugs (2016-2027)
20.4 Global Forecasted Production of Neurological Disorder Drugs by Region (2022-2027)
20.4.1 North America Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.3 Europe Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.7 Africa Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.9 South America Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Neurological Disorder Drugs Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Neurological Disorder Drugs by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Neurological Disorder Drugs by Country
21.2 East Asia Market Forecasted Consumption of Neurological Disorder Drugs by Country
21.3 Europe Market Forecasted Consumption of Neurological Disorder Drugs by Countriy
21.4 South Asia Forecasted Consumption of Neurological Disorder Drugs by Country
21.5 Southeast Asia Forecasted Consumption of Neurological Disorder Drugs by Country
21.6 Middle East Forecasted Consumption of Neurological Disorder Drugs by Country
21.7 Africa Forecasted Consumption of Neurological Disorder Drugs by Country
21.8 Oceania Forecasted Consumption of Neurological Disorder Drugs by Country
21.9 South America Forecasted Consumption of Neurological Disorder Drugs by Country
21.10 Rest of the world Forecasted Consumption of Neurological Disorder Drugs by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
